- Home
- DTIL
as 06-20-2025 4:00pm EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 51.6M | IPO Year: | 2019 |
| Target Price: | $47.00 | AVG Volume (30 days): | 74.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $11.09 | Next Earning Date: | 07-31-2025 |
| Revenue: | $51,141,000 | Revenue Growth: | -11.11% |
| Revenue Growth (this year): | -67.38% | Revenue Growth (next year): | 30.20% |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Buehler Kevin | DTIL | Director | Mar 26 '25 | Buy | $4.67 | 4,523 | $21,122.41 | 13,235 | |
| Brown Melinda | DTIL | Director | Mar 26 '25 | Buy | $4.75 | 1,839 | $8,735.25 | 9,057 | |
| Germano Geno J | DTIL | Director | Mar 25 '25 | Buy | $5.30 | 3,250 | $17,225.00 | 11,057 |
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
20 days ago
Will Tesla have to play catch up to Waymo's robotaxis?
Yahoo Finance
20 days ago
Why Scott Bessent wants to make it easier for banks to own Treasurys
GlobeNewswire
20 days ago
EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry
GlobeNewswire
20 days ago
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire
20 days ago
Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population
CNW Group
20 days ago
Statement by Minister Guilbeault on Portuguese Heritage Month
AFP
20 days ago
Man Utd sign Brazil forward Cunha from Wolves
Moneywise
20 days ago
‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins
Compare DTIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.